AzTrials
AzTrials

Necrotizing EnterocolitisNECqualNCT06032676

Qualitative Study of Surgeons With Prospective Patient Follow-up

An observational study of Necrotizing Enterocolitis, run by University Hospital Southampton NHS Foundation Trust at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Necrotising enterocolitis (NEC) is a devastating disease which causes severe bowel inflammation resulting in babies becoming critically unwell. It mainly affects premature babies (who can be born as early as 22 weeks) in the first few weeks of life. Read more about this study

Who is it for?
Ages Up to 4 months
Conditions the study is for
Necrotizing Enterocolitis
How many people
75 participants
Where
1 siteUnited Kingdom
Study dates
1 Jan 2024to 1 Oct 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 4 months
  • All sexes
  • No healthy volunteers
  • Child

Study population: Infant with necrotising enterocolitis undergoing review by paediatric surgeon.

Who may be able to join

  • Infant with suspected or confirmed NEC undergoing review by surgeon, regardless of outcome of that review (I.e. surgery indicated or not).

Who cannot join

  • Lack of consent from surgeon to undertake interview.
  • Lack of consent from parents to follow-up outcomes of infant.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

George S Bethell contact

+442381206146

g.s.bethell@soton.ac.uk

United Kingdom1 site, 1 recruiting
  • University Southampton NHS Foundation Trust

    Southampton, Hampshire, SO16 6YD

    Rachael Pulham, +442381205044, sponsor@uhs.nhs.uk

    Recruiting

Other trials in United Kingdom

About this study

Official title: Surgical Decision Making in Necrotising Enterocolitis - a Prospective Qualitative Study of Surgeons

Necrotising enterocolitis (NEC) is a devastating disease which causes severe bowel inflammation resulting in babies becoming critically unwell. It mainly affects premature babies (who can be born as early as 22 weeks) in the first few weeks of life. A quarter of babies don't respond to intensive care treatment and require surgery to remove bowel which has died to prevent them from getting sicker. Sadly, about a third of the most unwell babies don't survive and those that do have a high incidence of significant long-term health problems.

Deciding which babies will benefit from surgery is challenging and there are no objective methods used to do this currently. Surgeons must weigh up the risks and benefits of performing major surgery on a tiny baby in the knowledge that surgery itself may cause harm. This uncertainty causes delays in performing surgery. Those that have a delay are more likely to have a poor outcome.

Read more

In order to improve these unfavourable outcomes it is essential to understand and define current practice in detail (i.e. indications and timing for surgery) and understand how this may be associated with outcome. These outcomes are both short term, including mortality and ability to tolerate enteral nutrition, and long term which include neurodevelopmental outcomes at 2 years of life.

To do this the investigators will undertake a multicentre mixed methods study with qualitative interview of consultant paediatric surgeons shortly after making a decision to operate, or not, on a baby with NEC. The investigators will then take consent from the parents/guardian of the infant to follow-up their clinical outcomes using data linkage to routinely collected data, within the national neonatal research database. Outcomes of interest include survival, feeding outcomes, further surgical procedures and neurodevelopment at 2 years.

Read the detailed description

Necrotising enterocolitis (NEC) predominately affects pre-term infants and consists of a severe bowel inflammation which can lead to necrosis. The number of babies at highest risk of developing NEC is rising as survival of extremely preterm babies improves. Whilst unanswered questions remain regarding the aetiology of NEC, the clinical presentation is that of an acutely unwell baby, with abdominal distension requiring intensive care support due to activation of a systemic inflammatory response.

About a quarter of babies will require surgery due to bowel perforation, suspected necrotic bowel or failure to improve with intensive care treatment alone. Most commonly, ischaemic, non-viable gut is found at laparotomy and hence removed. In 1-in-20 surgical procedures the extent of the non-viable gut is so great that survival is not possible.

Surgical practice, including decision-making, in NEC has been previously shown to vary from surgeon to surgeon with no set criteria for when an infant is no longer responding to medical treatment and should have surgery. It can be particularly challenging given that babies with the disease are of extreme prematurity and some weigh as little as 500 grams. There is a real risk of causing harm during surgery hence it is essential that the benefits outweigh the risk. Unfortunately short and long-term outcomes for surgical NEC are poor including mortality in 35% following surgery and 59% of survivors experience neurodevelopmental problems. Recent evidence suggests that earlier surgery for NEC is beneficial and is associated with better outcomes than delayed surgery. Additionally, 20% of neonates with NEC die before surgery which is potentially avoidable with more effective identification of the need for surgery.

In order to improve these unfavourable outcomes it is essential to understand and define current practice in detail (i.e. indications and timing for surgery) and understand how this may be associated with outcome. These outcomes are both short term, including mortality and ability to tolerate enteral nutrition, and long term which include neurodevelopmental outcomes at 2 years of life.

This prospective mixed methods study is entirely observation and involves no intervention. Inclusion in the study is on the basis of fully informed consent.

Study flow is as follows:

  1. Initial surgeon interview - After the site setup, all consultant paediatric surgeons that treat infants with NEC will be invited to participate and provided with a participant information sheet along with a consent form. A baseline interview will be conducted with each participating surgeon via telephone based on hypothetical patients. The interview will follow a semi-structured guide. The interview will be recorded for transcription purposes. Thematic analysis will then be undertaken.
  2. Clinical Review of Infants with NEC by Consultant Surgeon - Infants will be eligible for inclusion if they have confirmed NEC or their most likely diagnosis is NEC, and are reviewed by a consultant surgeon for consideration of surgery at a study site. The local clinical team or research team will notify the study coordinator that this review has taken place.
  3. Qualitative surgeon interview about Review and Decision to Operate or Not - Qualitative interviews will be conducted via telephone as soon as possible after the clinical review by the surgeon. Interviews will be semi-structured, lasting approximately 10 minutes, and follow a topic guide. The interview will be recorded for transcription purposes. Thematic analysis will then be undertaken.
  4. Parent Consent and Data Collection - Following the qualitative interview of the surgeon, the parents of the infant who underwent clinical review will be approached for consent to record their infant's details and parental contact information. This process will occur prior to hospital discharge. Data will be collected to allow linkage to the National Neonatal Research Database (NNRD) which routinely collects data on infants admitted to neonatal units nationally.
  5. Initial Follow-up - 52 Weeks Corrected Gestational Age - Seven months after the end of data collection (1st May 2025), a list of patients using BadgerNet numbers and dates of birth, will be securely sent to the National Neonatal Research Database (NNRD) via NHS.net email in order to identify the infants on the NNRD. The requested data for each infant will be censored at 52 weeks corrected gestational age. The analysis will focus on identifying associations between the thematic interview analysis and the outcomes of the infants. These groups based on outcome are:
  • Survival and non survival
  • Survival and non-survival or parental nutrition dependence at discharge
  • Surgery after initial surgical review and continued medical management
  1. Further Follow-up - 2 Years of Age - the NNRD will be interrogated again on 1st January 2027 using the same procedures used during the initial follow-up. Additional outcomes of interest at this stage are two year outcome assessment date, developmental outcomes and cerebral palsy diagnosis. Associations between these outcomes and themes identified during surgeon interview will again be investigated.
Keywords
surgical decision making, neonatology, qualitative research, Necrotising enterocolitis
Medical subject headings
Enterocolitis, Necrotizing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06032676
Study groupRoleWhat they receive
Infants with necrotising enterocolitis reviewed by a surgeonInfant with suspected or confirmed NEC undergoing review by surgeon, regardless of outcome of that review (i.e. surgery indicated or not)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mortality

    Mortality

    Measured: At 52 weeks corrected gestational age and at 2 years age.

Secondary outcomes (1)
  1. Death or parental nutrition dependence

    Death or parental nutrition dependence versus survivors not requiring parental nutrition

    Measured: Hospital discharge (up to 52 weeks corrected gestational age)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Sep 2023
  2. Study start1 Jan 2024
  3. Primary completion1 Oct 2025 (estimated)
  4. Study completion1 Oct 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
75 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06032676
Sponsor's protocol ID
RHM CHI1209
Other IDs
NIHR
Acronym
NECqual
Status last verified
Apr 2024
First submitted
4 Sep 2023
Last updated
18 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Anonymised data available by reasonable request at end of study.

Questions about this trial

What is this clinical trial studying?

An observational study of Necrotizing Enterocolitis, run by University Hospital Southampton NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 18 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact George S Bethell (+442381206146, g.s.bethell@soton.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mortality (time frame: At 52 weeks corrected gestational age and at 2 years age.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in